“…Recurrent and repetitive VOEs may lead to frequent healthcare visits or interference with daily functioning, even in the absence of healthcare utilization, that negatively affect the quality of life for children and adults with SCD [National Heart, Lung and Blood Institute, National Institutes of Health (NHLBI, NIH), 2014; Jerrell et al, 2011;Tanabe et al, 2012]. Long-term management of SCD requires chronic medical care with access to education about prevention as well as current and future disease modifying and curative therapies (Wang et al, 2011;Alvarez et al, 2013;Yates et al, 2013;DeBaun et al, 2014;Lebensburger et al, 2015;McGann and Ware, 2015;Fitzhugh et al, 2017;Niihara et al, 2018;Quinn, 2018;Krishnamurti et al, 2019). In addition to hydroxyurea, other recently FDA approved therapies include voxelotor, L-glutamine, and crizanlizumab (Ataga et al, 2017;Howard et al, 2019;Vichinsky et al, 2019).…”